STK899704 

STK899704 is a tubulin inhibitor. STK899704 inhibits microtubule polymerization, leading to microtubule depolymerization. STK899704 exhibits broad-spectrum inhibitory activity against various cancer cell lines, including cervical cancer, breast cancer, and lung cancer, with IC₅₀ values ​​ranging from 0.2 to 1.0 μM. STK899704 disrupts the mitotic spindle structure, inducing G2/M phase cell cycle arrest. STK899704 inhibits the migration ability of HT29 cells by downregulating the FAK-MEK-ERK signaling pathway, thereby suppressing the expression and activity of MMP-2 and MMP-9. STK899704 activates caspase-3/7/8/9, leading to PARP cleavage and inducing apoptosis. STK899704 induces cellular senescence through the p53 pathway. STK899704 exhibits significant anti-tumor effects in mouse skin cancer. STK899704 can be used in research on skin cancer, lung cancer, colon cancer, and other cancers^[1][2][3].

453.49

C₂₇H₂₃N₃O₄

1578247-29-6

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Park CW, et al. The Novel Small Molecule STK899704 Promotes Senescence of the Human A549 NSCLC Cells by Inducing DNA Damage Responses and Cell Cycle Arrest. Front Pharmacol. 2018 Apr 16;9:163.  [Content Brief]

  [2]. Jang HJ, et al. STK899704 inhibits stemness of cancer stem cells and migration via the FAK-MEK-ERK pathway in HT29 cells. BMB Rep. 2018 Nov;51(11):596-601.  [Content Brief]

  [3]. Sakchaisri K, et al. Anticancer activity of a novel small molecule tubulin inhibitor STK899704. PLoS One. 2017 Mar 15;12(3):e0173311.  [Content Brief]